Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Actiq Now Available In The U.S. For Breakthrough Cancer Pain ABBOTT PARK, IL - March 31, 1999 -- Abbott Laboratories’ Actiq(R) (oral transmucosal fentanyl citrate) is now available in the United States for breakthrough cancer pain in patients who are already receiving -- and tolerant to -- opioid therapy for their underlying, persistent cancer pain. Breakthrough cancer pain is a flare of severe cancer pain that breaks through the medication being administered at regular intervals for persistent cancer pain. Breakthrough cancer pain is a component of chronic cancer pain that is particularly difficult to treat due to its severity, rapid onset and unpredictability. More than 800,000 cancer patients suffer with breakthrough cancer pain. Episodes of breakthrough cancer pain develop rapidly and can last from one to three hours, leaving patients in excruciating pain between their regularly scheduled doses of pain medication. Actiq is a powerful pain medication that is administered orally using Anesta's proprietary oral transmucosal system (OTS) for drug delivery. The product is a medicated drug matrix on a handle. Actiq dissolves in the mouth and is absorbed by the highly permeable oral mucosa, allowing for the medication to enter the bloodstream through the lining of the mouth. The most common adverse events observed with Actiq use in breakthrough cancer pain patients are somnolence (sleepiness), nausea, vomiting and dizziness. These types of events are generally associated with opioid therapy. The most clinically meaningful adverse event is the potential for respiratory depression. Actiq is contraindicated in the management of acute or postoperative pain and must not be used in patients who cannot tolerate opioids. It is intended to be used only in the care of cancer patients by oncologists and pain specialists who are skilled in the use of Schedule II opioids to treat cancer pain. Related Links: Actiq, Abbott Laboratories E-mail this page to a friend or colleague! To print, use this version